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Abstract
Scleroderma renal crisis is a serious complication that can develop in certain patients with systemic sclerosis. Some risks
have been identified as potential triggers of scleroderma renal crisis, including the high-dose oral corticosteroids. Here, we
present a patient who developed clinically severe systemic sclerosis and scleroderma renal crisis after exposure to oral
corticosteroids and intravitreal vascular endothelial growth factor blockade with bevacizumab for cotton wool spots. The
patient’s scleroderma renal crisis was severe, progressive, and refractory to the standard of care therapy: oral captopril.
Biopsy showed a diffuse thrombotic microangiopathy and findings consistent with scleroderma renal crisis. We hypothesize
that depletion of systemic vascular endothelial growth factor with intravitreal anti–vascular endothelial growth factor
injections likely contributed to the particularly severe presentation seen in this case. Though the finding of a monoclonal
gammopathy of undetermined significance is another complicating factor, this case suggests that vascular endothelial growth
factor inhibition may be a newly recognized trigger of scleroderma renal crisis.
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Introduction
Thrombotic microangiopathy (TMA) has been noted to
develop in many disease states that have both inflammation
and endothelial injury.1 There are many complex pathways
involved; however, it has become clear that endothelial
injury can occur more easily in certain genetically susceptible individuals.2 It has also been observed that if endothelial
damage and complement activation are sufficiently severe,
TMA can occur despite the appearance of an apparently
benign genetic environment.3 Scleroderma renal crisis (SRC)
usually presents with a TMA that occurs within the context
of malignant hypertension (MHT) and progressive renal
dysfunction.4
It is important to note that MHT is not always observed,
and renal-limited TMAs related to SRC have been reported
in individuals without findings of hypertension.5–7 The relationship between complement activation, rheumatologic

syndromes, and endothelial dysfunction plays a key role in
patients with MHT, SRC, and TMA. Timmermans et al.8
recently reported the association between some genetic
abnormalities to chronic hypertension with renal-limited
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Figure 1. Schematic of causal theories of hypertension and
thrombotic microangiopathy.

Black arrows explain standard theory that hypertension causes endothelial
injury and complement activation. Red arrows show alternative theory,
favored by pathological review that thrombotic microangiopathy resulting
from genetic causes triggers hypertension and results in chronic irreversible
vascular injury. Complement blockade maybe efficacious if it blocks chronic
vascular injury, but development of vascular injury presages irreversible
renal dysfunction.
CM: complement mediated; HTN: hypertension; TMA: thrombotic
microangiopathy.

TMA. Figure 1 explains the association between complement activation, genetic complement dysfunction, and
endothelial shear stress that can create the conditions for a
TMA to develop.
The use of high-dose corticosteroids is known to increase
the risk of SRC, thus explaining why steroid therapy has
fallen out of favor as a treatment of systemic sclerosis (Ssc).9
The current treatment for SRC consists of renin angiotensin
aldosterone system (RAAS) blockade and low dose aspirin
for anti-platelet effect.10,11 The clinical benefit does not seem
to be uniform, and there are no proven second- or third-line
treatment options.12 Experimental therapy with anti-endothelin agents, plasmapheresis, and complement blockade has
been described for SRC.13
Another agent recently noted to be systemically absorbed
and proven to disrupt systemic vascular endothelial growth
factor (VEGF) levels are intravitreal injections of VEGF
inhibiting monoclonal antibodies.14–16 We present a case of
SRC that initially developed after the patient was exposed to
corticosteroids. He was subsequently exposed to intravitreal
VEGF blockade and had rapidly progressive hypertension
with subacute kidney injury refractory to the standard of care
therapy. We thus bring attention to a possible role for VEGF
blockade in accelerating SRC in this patient who received
intravitreal injections of bevacizumab.

Case report
A 37-year-old male developed a sudden progressive onset of
worsening skin thickening, initially localized to his torso but
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had since begun to spread. There was no cyanotic discoloration
of extremities that would suggest Raynaud’s phenomenon. The
patient also noted progressive weight loss up to 20–30 pounds
(lbs) over the first 3 months of his initial presentation. The
patient described fatigue, but without wheezing or dyspnea.
His systolic blood pressure was initially 100–110 mmHg,
and he had no previous history of hypertension. His renal
function was within normal range, with a serum creatinine of
0.8 mg/dL. Notably, he had a history of hepatitis B, treated
with entecavir, without evidence of active disease (precluded
use of B cell depletion therapy). His serological testing
revealed a negative anti-nuclear antibody (titer of 0), negative anti-Smith antibodies, and negative anti-ribonucleoprotein. Anti-Scl-70 (anti-topoisomerase I antibody) levels were
detected at a low level, but within the reference range (3–
4 AU/mL). The triple negative profile was unusual, and as
such more investigation was warranted before considering a
diagnosis of Ssc.
A skin biopsy was sought from the patient’s left upper
extremity at a site of severe skin thickening. The area of skin
thickening was representative of changes over much of the
patient’s skin surface, his modified Rodnan skin score was
31, and nail bed capillaroscopy exam was positive and suggestive of Ssc. There was no evidence of pericardial friction
rub noted on exam, and echocardiography did not reveal pulmonary hypertension or a pericardial effusion.
The skin biopsy sample was read by the pathologist as
suspicious for morphea versus scleroderma/Ssc. His renal
function was normal until that time, and he had no gadolinium exposure. We clarified the point about gadolinium exposure to ensure that the patient did not have nephrogenic
systemic fibrosis (NSF). The diagnosis of Ssc was more rigorously suspected on the basis of the skin biopsy results and
careful clinical exam that revealed diffuse skin thickening
and sclerodactyly. He was subsequently started on mycophenolate mofetil for treatment of Ssc.
A curious feature of his presentation was the finding of an
IgG lambda monoclonal light chain of undetermined significance at 1.1 g/dL. A bone marrow biopsy was obtained and
showed a normal cellular marrow, of which 10% were
lambda restricted plasma cells, confirmed by flow cytometry. Cytogenetics/fluorescent in situ hybridization demonstrated a gain of 1q, gain of 5q, monosomy 13, and 14q
minus ranging from 67% to 94%, karyotype was 46, XY.
Given the complexity of this case, he saw multiple providers at various health care centers. He was started on high-dose
oral corticosteroids (60 mg), the reason for starting this agent
was not immediately apparent to our team. Subsequently, he
had a rise in blood pressure and serum creatinine from 0.8 to
1.1 mg/dL. This occurred abruptly after starting the prednisone, 3 months after his initial presentation. The patient’s
blood pressure rose from 120–130 mmHg systolic baseline to
140–150 mmHg during this time.
He developed blurry vision and was referred to ophthalmology where dilated eye exam revealed “cotton wool
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Figure 2. Serum creatinine (mg/dL) versus months after presentation with SRC.

BP: blood pressure; mg/dL: milligrams/deciliter; DBP: diastolic blood pressure; H: hospitalization for renal crisis; mmHg: millimeters of mercury; RBx:
renal biopsy; SBP: systolic blood pressure; SBx: skin biopsy; sCr: serum creatinine; SRC: scleroderma renal crisis. Black arrow: corticosteroids 1 mg/kg;
Red arrow: bevacizumab 1.25 mg injections × 2; Green arrow: renal replacement therapy—hemodialysis.

spots.” He was given 1.25 mg intravitreally injected bevacizumab on two occasions. A week later, an even sharper rise
in blood pressure was noted and accompanied by worsening
serum Cr to 1.4 mg/dL. Figure 2 shows the trends of serum
creatinine, systolic blood pressure, and diastolic blood pressures for this case. The data are presented in months after
presentation to preserve anonymity.
He was admitted a week later with severe hypertension
with systolic blood pressures of 200–220 mmHg. A marked
increase in proteinuria from undetectable to a urine protein
to creatinine ratio of 1-gram protein per gram creatinine was
noted during this admission. A renal ultrasound and Doppler
evaluation revealed normal sized kidneys without any evidence of atrophy or size mismatch, along with no evidence
of renal artery stenosis. Given the sudden change in blood
pressure, renal function, proteinuria, and recent exposure to
oral corticosteroids, SRC was suspected. A complementmediated TMA related to intravitreal VEGF inhibition could
also not be ruled out. As such, a renal biopsy was obtained
after his blood pressure was controlled to look for these diagnostic possibilities.
The patient’s renal biopsy (Figure 3) contained 57 glomeruli (1 globally sclerotic) and light microscopy demonstrated
arteries with near-complete luminal occlusion by fibrointimal
proliferation and adjacent ischemic tubulopathy. Mucoid intimal hyperplasia was noted in several arteries as well on trichrome stain, along with “onion skin” changes and bloodless
glomeruli. Some rare glomeruli exhibit segmental small
luminal thromboses. There was diffuse but early/evolving

tubular atrophy as well as early interstitial fibrosis associated
with the ischemic tubulopathy. Immunofluorescence was
negative for any immune complex staining.
A Congo-red stain was negative for amyloid deposition.
Electron microscopic studies demonstrated marked ischemictype corrugation of glomerular capillary loops as well as extensive endothelial cell swelling often with near-complete luminal
occlusion. Glomerular subendothelial spaces were widened
and showed occasional neomembrane formation. Luminal
platelet aggregates were present. No electron dense, organized,
or crystalline deposits were present in any compartment. The
overall diagnosis was a diffuse TMA with arterial predominance, consistent with Ssc-associated renal disease.
The patient’s lactate dehydrogenase showed a low-level
elevation at 344 IU/L, which is near the upper limit of normal. A disintegrin and metalloproteinase level motif #1,
member 13 (ADAMTS13) level was 75%, ruling out
ADAMTS13 deficiency and thrombotic thrombocytopenic
purpura (TTP). International normalized ratio was normal
at 1 with a normal prothrombin time of 10.5 s, and a normal activated partial thromboplastin time at 28 s. Platelets
were normal ranging 300,000–358,000/µL, hemoglobin
was 11.8 g/dL, and there was no evidence of microangiopathic hemolysis. Schistocytes were not noted during the
patient’s course at any time. Reticulocytes were normal at
1.3%, iron saturation was 43%, and vitamin B12 level was
451 pg/mL. Shigatoxin was negative in the patient’s stool
specimen. The data support a renal-limited TMA without
peripheral hemolysis.
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Figure 3. Features of active thrombotic microangiopathy on renal biopsy: (a) arteries with near-complete luminal occlusion by
fibrointimal proliferation (arrows) and adjacent ischemic tubulopathy (periodic acid Schiff stain, 100×); (b) artery with mucoid intimal
hyperplasia (arrow) (trichrome stain 200×); (c) artery with “onion skin” change (trichrome stain 400×); and (d) “bloodless” glomerulus
(H&E stain, 400×).

Serum VEGF level obtained weeks after injection with
bevacizumab was 52 pg/mL. This level is near to lower limit
of normal, and could suggest some level of VEGF depletion.
The lack of an elevated level also rules out POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and
skin changes) syndrome which was in differential diagnosis,
and is characterized by a high serum VEGF level.
Complement genetics were obtained and demonstrated a
heterozygous, missense variant (c.1058C>T) of membrane
cofactor protein (MCP) (alanine 353 to valine 353 substitution). This was previously associated with atypical hemolytic uremic syndrome (aHUS) presented in the case series of
Fang et al.17 in 2008. The risks and benefits of complement
blockade were explained to patient, who was started on low
dose 81-mg aspirin and captopril titration as inpatient and
outpatient as the standard of care. The patient was made
aware of the favorable response of eculizumab in 66.7% of
SRC cases.18–24
The patient ultimately declined use of complement blockade despite the copious explanation of benefits, given the
risks reported for meningitis despite existence of vaccines
and prophylactic antibiotics. The patient’s renal function continued to worsen with serum creatinine rising to 1.9 mg/dL, to
2.7 mg/dL, and then to 7 mg/dL over the course of 5 months.
Currently, he is receiving plasmapheresis to improve renal
function, and renal replacement therapy. The plan is to pursue
renal transplantation with complement blockade with a C5 or
C3 blocking agent, depending on availability, and the patient’s
willingness to try this adjunct therapy.

Discussion
Ssc-induced renal disease covers a wide spectrum, from a
chronic interstitial nephritis with resulting mild proteinuria

and indolent renal dysfunction, to the more severe complication of SRC.12 The presentation of renal crisis includes
severe hypertension with findings of end organ dysfunction
with the risk of irreversible renal failure.4 The pathological
findings of SRC are generally an arterial/arteriolar predominant TMA often with marked subendothelial edema and
fibrointimal proliferation resulting in prominent onion skinning–type change with or without concurrent glomerular
thrombosis.4
This particular patient’s presentation is unique in that a
week before the patient was hospitalized with MHT, he
received intravitreal VEGF injections for cotton wool spots
in the eye by ophthalmology. There are now increasing
reports of intravitreal injections resulting in VEGF depletion and glomerular disease including TMA, collapsing
focal and segmental sclerosis (FSGS), as well as other
causes of nephrotic syndrome.14–16,25–27 The renal biopsy
findings we presented could be compatible with TMA from
VEGF depletion and from SRC. Given the presence of Ssc
clinically predating the intravitreal VEGF inhibition injections, it was surmised that the patient’s Ssc was likely exacerbated by VEGF blockade and hypertension as well as the
oral corticosteroids.
Given the refractory nature of the TMA, the evidence for
eculizumab was reviewed with the patient, but he felt that the
risk of meningitis outweighed the potential benefit. In all,
nine patients with Ssc syndromes were treated with eculizumab, with six patients showing a positive response. Table 1
details the cases of SRC treated with eculizumab and the corresponding clinical response data.18–24
In addition, this patient’s genetic testing led to some
equivocal findings of alleles not generally thought to be pathogenic. We cannot exclude a yet undescribed role for these
genetic variants which affect susceptibility to complement
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Table 1. Cases of eculizumab therapy in patients with TMA due to SRC.
Reference #

Eculizumab
treated

Age

Gender

Renal recovery

ESRD

Death

[18]

2
1
1
1
1
1
2

56, 63
28
62
56
46
40
28, 48

M, M
F
M
M
F
F
F, F

50%, 1 with CKD
0%
100%
100%
100%
100%
50%

50%
100%
0%
0%
0%
0%
50%

0%
100%
0%
0%
0%
0%
50%

[19]
[20]
[21]
[22]
[23]
[24]

CKD: chronic kidney disease; ESRD: end stage renal disease; F: female; M: male.

Figure 4. The interplay between genetic risk and trigger strength in triggering thrombotic microangiopathy.
aHUS: atypical hemolytic uremic syndrome; Amp: amplification; Comp: complement; TMA: thrombotic microangiopathy.

amplifying and endothelium disruptive insults. It is probable
that genetic susceptibility and trigger strength should both be
taken into account when TMA episodes are observed. A “sliding scale” of genetic risk and trigger strength are likely operating concurrently,28 with more purely genetic presentations
resulting from minor environmental triggering exposures and
more acquired presentations occurring from severe triggers.1
See Figure 4 for a diagram illustrating this concept in TMA
susceptibility.
The patient’s monoclonal gammopathy also adds complexity to this case. TMA is considered to fall within the
monoclonal gammopathy of renal significance (MGRS)
spectrum of lesions.29 Furthermore, paraneoplastic scleroderma like-tissue reactions have been reported.30 The degree
to which the patient’s underlying plasma cell dyscrasia may
have influenced this patient’s clinical course are uncertain.
The renal biopsy did not show any evidence for any other
MGRS-associated lesion such as amyloidosis, light chain
proximal tubulopathy, light chain cast nephropathy, light
chain deposition disease, FSGS, or heavy chain deposition
disease.31,32

Conclusion
We report a 37-year old male w/severe Ssc and the onset of
SRC after oral corticosteroid treatment, and intravitreal VEGF
blockade. More work remains to be done regarding the relationship of VEGF signaling and SRC. The effects of alternative complement pathway and VEGF blockade remain
interesting due to the association of SRC with TMA. Oral corticosteroids should be avoided in Ssc, and we believe caution
should be used when prescribing intravitreal VEGF blockade
in patients with Ssc. Treatment with complement blockade
needs to be thoroughly studied due to pathophysiological
overlap between SRC and complement-mediated TMA.
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